Catherine Markopoulou

Dr. Catherine Markopoulou

Laboratory of Pharmaceutical Analysis, Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
AOAndreas Ouranidis
Andreas Ouranidis
TVTheofanis Vavilis
Theofanis Vavilis
EMEvdokia Mandala
Evdokia Mandala
CDChristina Davidopoulou
Christina Davidopoulou
ESEleni Stamoula
Eleni Stamoula
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis
In the quest for a formidable weapon against the SARS-CoV-2 pandemic, mRNA therapeutics have stolen the spotlight. mRNA vaccines are a prime example of the benefits of mRNA approaches towards a broad array of clinical entities and druggable targets. Amongst these benefits is the rapid cycle “from design to production” of an mRNA product compared to their peptide counterparts, the mutability of the production line should another target be chosen, the side-stepping of safety issues posed by DNA therapeutics being permanently integrated into the transfected cell’s genome and the controlled precision over the translated peptides. Furthermore, mRNA applications are versatile: apart from vaccines it can be used as a replacement therapy, even to create chimeric antigen receptor T-cells or reprogram somatic cells. Still, the sudden global demand for mRNA has highlighted the shortcomings in its industrial production as well as its formulation, efficacy and applicability. Continuous, smart mRNA manufacturing 4.0 technologies have been recently proposed to address such challenges. In this work, we examine the lab and upscaled production of mRNA therapeutics, the mRNA modifications proposed that increase its efficacy and lower its immunogenicity, the vectors available for delivery and the stability considerations concerning long-term storage.

13 August 2015 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
VMVarvara J. Mandra
Varvara J. Mandra
MKMaria G. Kouskoura
Maria G. Kouskoura
CMCatherine Markopoulou
Catherine Markopoulou

15 April 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AOAndreas Ouranidis
Andreas Ouranidis
ATANASTASIA TSIAXERLI
ANASTASIA TSIAXERLI
Elisavet VardakaElisavet Vardaka
Elisavet Vardaka
CMCatherine Markopoulou
Catherine Markopoulou
Constantinos ZacharisConstantinos Zacharis
Constantinos Zacharis
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis
Sildenafil is a potent selective, reversible inhibitor of phosphodiesterase type 5 (PDE5) approved for the treatment of erectile dysfunction and pulmonary arterial hypertension. Whilst twenty years have passed since its original approval by the US Food and Drug Administration (USFDA), sildenafil enters the fourth industrial era catalyzing the treatment advances against erectile dysfunction and pulmonary hypertension. The plethora of detailed clinical data accumulated and the two sildenafil analogues marketed, namely tadalafil and vardenafil, signify the relevant therapeutic and commercial achievements. The pharmacokinetic and pharmacodynamic behavior of the drug appears complex, interdependent and of critical importance whereas the treatment of special population cohorts is considered. The diversity of the available formulation strategies and their compatible administration routes, extend from tablets to bolus suspensions and from per os to intravenous, respectively, inheriting the associated strengths and weaknesses. In this comprehensive review, we attempt to elucidate the multi-disciplinary elements spanning the knowledge fields of chemical synthesis, physicochemical properties, pharmacology, clinical applications, biopharmaceutical profile, formulation approaches for different routes of administration and analytical strategies, currently employed to guide the development of sildenafil-based compositions.

20 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
PMParaskevi Kyriaki Monou
Paraskevi Kyriaki Monou
Eleftherios AndriotisEleftherios Andriotis
Eleftherios Andriotis
EMElisavet Mitsouli
Elisavet Mitsouli
NMNikoleta Moutafidou
Nikoleta Moutafidou
DFDimitrios Fatouros
Dimitrios Fatouros
Buccal films containing two vitamins, i.e., thiamine hydrochloride (THCl) and nicotinic acid (NA), were fabricated via two-dimensional (2D) inkjet printing. For the preparation of buccal films, solubility studies and rheological evaluations were conducted in distilled water and propylene-glycol (PG) as main solvent and viscosity/surface tension modifier, respectively. The increased solubility in the solvents’ mixture indicated that manufacturing of several doses of the THCl and NA is achievable. Various doses were deposited onto sugar-sheet substrates, by increasing the number of printing passes. The physiochemical characterization (SEM, DSC, FTIR) revealed that inkjet printing does not affect the solid state of the matrix. Water uptake studies were conducted, to compare the different vitamin-loaded formulations. The in vitro release studies indicated the burst release of both vitamins within 10 min, a preferable feature for buccal administration. The in vitro permeation studies indicated that higher concentrations of the vitamins onto the sugar sheet improved the in vitro permeation performance of printed formulations.

3 October 2003 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CMCatherine Markopoulou
Catherine Markopoulou
JKJ.E Koundourelllis
J.E Koundourelllis

18 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
ETEleni Tsanaktsidou
Eleni Tsanaktsidou
Christina KaravasiliChristina Karavasili
Christina Karavasili
Constantinos ZacharisConstantinos Zacharis
Constantinos Zacharis
DFDimitrios Fatouros
Dimitrios Fatouros
CMCatherine Markopoulou
Catherine Markopoulou
One of the most challenging goals in modern pharmaceutical research is to develop models that can predict drugs’ behavior, particularly permeability in human tissues. Since the permeability is closely related to the molecular properties, numerous characteristics are necessary in order to develop a reliable predictive tool. The present study attempts to decode the permeability by correlating the apparent permeability coefficient (Papp) of 33 steroids with their properties (physicochemical and structural). The Papp of the molecules was determined by in vitro experiments and the results were plotted as Y variable on a Partial Least Squares (PLS) model, while 37 pharmacokinetic and structural properties were used as X descriptors. The developed model was subjected to internal validation and it tends to be robust with good predictive potential (R2Y = 0.902, RMSEE = 0.00265379, Q2Y = 0.722, RMSEP = 0.0077). Based on the results specific properties (logS, logP, logD, PSA and VDss) were proved to be more important than others in terms of drugs Papp. The models can be utilized to predict the permeability of a new candidate drug avoiding needless animal experiments, as well as time and material consuming experiments.